MAP3K5 and brain ischemia: These findings confirm results of previous studies, showing that genetic knockdown or pharmacological inhibition of Ask-1 or FOXO-1 reduced brain damage after brain damage caused by cerebral ischemia and traumatic brain injury [54–56], suggesting that Ask-1 and FOXO-1 are potential therapeutic targets in ICH.